{
    "1": {
        "question": "What was the primary objective of the study?",
        "options": {
            "A": "To investigate the effect of anticoagulation on patients with nonvalvular atrial fibrillation",
            "B": "To compare the outcomes of patients with nonvalvular atrial fibrillation and systemic atherosclerosis treated with OAC + antiplatelet versus OAC alone",
            "C": "To evaluate the safety of anticoagulation in patients with nonvalvular atrial fibrillation",
            "D": "To assess the efficacy of antiplatelet therapy in patients with nonvalvular atrial fibrillation",
            "E": "To investigate the relationship between nonvalvular atrial fibrillation and systemic atherosclerosis",
            "I don't know": ""
        }
    },
    "2": {
        "question": "What was the study design?",
        "options": {
            "A": "Prospective cohort study",
            "B": "Retrospective cohort study",
            "C": "Randomized controlled trial",
            "D": "Case-control study",
            "E": "Cross-sectional study",
            "I don't know": ""
        }
    },
    "3": {
        "question": "How many patients were included in the study?",
        "options": {
            "A": "6912",
            "B": "1353",
            "C": "445",
            "D": "296",
            "E": "149",
            "I don't know": ""
        }
    },
    "4": {
        "question": "What was the median age of the patients included in the study?",
        "options": {
            "A": "65",
            "B": "70",
            "C": "75",
            "D": "80",
            "E": "85",
            "I don't know": ""
        }
    },
    "5": {
        "question": "What percentage of patients were male?",
        "options": {
            "A": "40%",
            "B": "50%",
            "C": "59.3%",
            "D": "60%",
            "E": "70%",
            "I don't know": ""
        }
    },
    "6": {
        "question": "What was the most common atherosclerotic disease in the study population?",
        "options": {
            "A": "Cerebral atherosclerosis",
            "B": "Coronary artery occlusive disease (CAOD)",
            "C": "Peripheral artery occlusive disease (PAOD)",
            "D": "Aortic arch atheroma",
            "E": "Carotid artery stenosis",
            "I don't know": ""
        }
    },
    "7": {
        "question": "What was the primary outcome of the study?",
        "options": {
            "A": "All-cause mortality",
            "B": "Recurrent ischemic stroke",
            "C": "Myocardial infarction",
            "D": "Bleeding events",
            "E": "All-composite outcome",
            "I don't know": ""
        }
    },
    "8": {
        "question": "What was the hazard ratio for all-cause mortality in the OAC + antiplatelet group compared to the OAC alone group?",
        "options": {
            "A": "0.48",
            "B": "0.63",
            "C": "0.91",
            "D": "1.01",
            "E": "1.12",
            "I don't know": ""
        }
    },
    "9": {
        "question": "What was the p-value for the difference in all-cause mortality between the OAC + antiplatelet group and the OAC alone group?",
        "options": {
            "A": "0.045",
            "B": "0.087",
            "C": "0.121",
            "D": "0.159",
            "E": "0.365",
            "I don't know": ""
        }
    },
    "10": {
        "question": "What was the most common antiplatelet agent used in the study?",
        "options": {
            "A": "Aspirin",
            "B": "Clopidogrel",
            "C": "Triflusal",
            "D": "Cilostazol",
            "E": "Aggrenox",
            "I don't know": ""
        }
    },
    "11": {
        "question": "What percentage of patients in the OAC + antiplatelet group received a single antiplatelet agent?",
        "options": {
            "A": "80%",
            "B": "90%",
            "C": "96.6%",
            "D": "98%",
            "E": "100%",
            "I don't know": ""
        }
    },
    "12": {
        "question": "What was the median follow-up period in the study?",
        "options": {
            "A": "6 months",
            "B": "1 year",
            "C": "2 years",
            "D": "3 years",
            "E": "5 years",
            "I don't know": ""
        }
    },
    "13": {
        "question": "What was the incidence of all-composite outcome in the study population?",
        "options": {
            "A": "10%",
            "B": "15%",
            "C": "20.9%",
            "D": "25%",
            "E": "30%",
            "I don't know": ""
        }
    },
    "14": {
        "question": "What was the most common cause of death in the study population?",
        "options": {
            "A": "Cardiovascular death",
            "B": "Cancer",
            "C": "Infection",
            "D": "Bleeding",
            "E": "Unknown",
            "I don't know": ""
        }
    },
    "15": {
        "question": "What was the hazard ratio for myocardial infarction in the OAC + antiplatelet group compared to the OAC alone group?",
        "options": {
            "A": "0.00",
            "B": "0.34",
            "C": "0.60",
            "D": "1.01",
            "E": "1.12",
            "I don't know": ""
        }
    },
    "16": {
        "question": "What was the p-value for the difference in myocardial infarction between the OAC + antiplatelet group and the OAC alone group?",
        "options": {
            "A": "<0.001",
            "B": "0.045",
            "C": "0.087",
            "D": "0.121",
            "E": "0.365",
            "I don't know": ""
        }
    },
    "17": {
        "question": "What was the incidence of bleeding events in the study population?",
        "options": {
            "A": "5%",
            "B": "7.9%",
            "C": "10%",
            "D": "15%",
            "E": "20%",
            "I don't know": ""
        }
    },
    "18": {
        "question": "What was the hazard ratio for bleeding events in the OAC + antiplatelet group compared to the OAC alone group?",
        "options": {
            "A": "0.91",
            "B": "1.01",
            "C": "1.12",
            "D": "1.50",
            "E": "2.00",
            "I don't know": ""
        }
    },
    "19": {
        "question": "What was the p-value for the difference in bleeding events between the OAC + antiplatelet group and the OAC alone group?",
        "options": {
            "A": "0.045",
            "B": "0.087",
            "C": "0.121",
            "D": "0.760",
            "E": "0.982",
            "I don't know": ""
        }
    },
    "20": {
        "question": "What was the conclusion of the study regarding the use of OAC + antiplatelet in patients with nonvalvular atrial fibrillation and systemic atherosclerosis?",
        "options": {
            "A": "OAC + antiplatelet was associated with a lower risk of all-cause mortality and myocardial infarction",
            "B": "OAC + antiplatelet was associated with a higher risk of bleeding events",
            "C": "OAC + antiplatelet had no effect on outcomes",
            "D": "OAC + antiplatelet was associated with a higher risk of ischemic stroke",
            "E": "OAC + antiplatelet was associated with a lower risk of cardiovascular death",
            "I don't know": ""
        }
    }
}